[{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Reports Preclinical Data Shwing Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals for Voruciclib
ME-522 (voruciclib), an investigational selective oral CDK9 inhibitor, in combination with venetoclax (Venclexta®), a BCL2 inhibitor is being evaluated for the treatment of relapsed and refractory acute myeloid leukemia.
ME-522 (voruciclib) is an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor with potential to treat Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies